Estrogens and insulin-like growth factors (IGFs) act as mitogens promoting cell proliferation in normal breast tissue as well as in breast carcinomas. Both hormones have been shown to play a role in the development of breast cancer and were found to activate multiple signaling pathways leading to proliferation of human breast cancer cell lines in vitro. Originally, it was considered that these agents manifest their mitogenic actions through separate pathways, but a growing body of evidence suggests that the IGF- and estrogen-mediated signaling pathways are intertwined. 17beta-Estradiol (E2) has been shown to enhance IGF signaling at multiple levels. E2 treatment of breast cancer cells alters expression of nearly all of the IGF family members including IGF-I, IGF-II, IGF-binding proteins, IGF type I receptor (IGF-RI), and insulin receptor substrate 1. The ligand-bound estrogen receptor has been reported to bind to and to activate the IGF-RI directly. Vice versa, IGF signaling has been reported to enhance estrogen receptor activation in human breast cancer cells by inducing phosphorylation of the estrogen receptor. Finally, several groups have described synergistic effects of the combination of E2 and IGF-I on S phase entry in breast tumor cell lines. Here, we review recent, often contradictory, reports describing the effects of E2 and IGFs on the proliferation of breast tumor cells, with special emphasis on the synergistic effects of the two hormones.

This article has been cited by other articles:

				G. Pandini, M. Genua, F. Frasca, S. Squatrito, R. Vigneri, and A. Belfiore 17{beta}-Estradiol Up-regulates the Insulin-like Growth Factor Receptor through a Nongenotropic Pathway in Prostate Cancer Cells Cancer Res., September 15, 2007; 67(18): 8932 - 8941. [Abstract] [Full Text] [PDF]

				F. Xue and K. B Michels Diabetes, metabolic syndrome, and breast cancer: a review of the current evidence Am. J. Clinical Nutrition, September 1, 2007; 86(3): 823S - 835S. [Abstract] [Full Text] [PDF]

				M. S. Baquedano, N. Saraco, E. Berensztein, C. Pepe, M. Bianchini, E. Levy, J. Goni, M. A. Rivarola, and A. Belgorosky Identification and Developmental Changes of Aromatase and Estrogen Receptor Expression in Prepubertal and Pubertal Human Adrenal Tissues J. Clin. Endocrinol. Metab., June 1, 2007; 92(6): 2215 - 2222. [Abstract] [Full Text] [PDF]

				M. P.V. Shekhar, S. Santner, K. A. Carolin, and L. Tait Direct Involvement of Breast Tumor Fibroblasts in the Modulation of Tamoxifen Sensitivity Am. J. Pathol., May 1, 2007; 170(5): 1546 - 1560. [Abstract] [Full Text] [PDF]

				K. Dhar, S. Banerjee, G. Dhar, K. Sengupta, and S. K. Banerjee Insulin-like Growth Factor-1 (IGF-1) Induces WISP-2/CCN5 via Multiple Molecular Cross-talks and Is Essential for Mitogenic Switch by IGF-1 Axis in Estrogen Receptor-Positive Breast Tumor Cells Cancer Res., February 15, 2007; 67(4): 1520 - 1526. [Abstract] [Full Text] [PDF]

				Y. Mitsui, S. Mochizuki, T. Kodama, M. Shimoda, T. Ohtsuka, T. Shiomi, M. Chijiiwa, T. Ikeda, M. Kitajima, and Y. Okada ADAM28 Is Overexpressed in Human Breast Carcinomas: Implications for Carcinoma Cell Proliferation through Cleavage of Insulin-like Growth Factor Binding Protein-3. Cancer Res., October 15, 2006; 66(20): 9913 - 9920. [Abstract] [Full Text] [PDF]

				J. M. Knowlden, I. R. Hutcheson, D. Barrow, J. M. W. Gee, and R. I. Nicholson Insulin-Like Growth Factor-I Receptor Signaling in Tamoxifen-Resistant Breast Cancer: A Supporting Role to the Epidermal Growth Factor Receptor Endocrinology, November 1, 2005; 146(11): 4609 - 4618. [Abstract] [Full Text] [PDF]

				D Montanaro, M Maggiolini, A G Recchia, R Sirianni, S Aquila, L Barzon, F Fallo, S Ando, and V Pezzi Antiestrogens upregulate estrogen receptor {beta} expression and inhibit adrenocortical H295R cell proliferation J. Mol. Endocrinol., October 1, 2005; 35(2): 245 - 256. [Abstract] [Full Text] [PDF]

				J M Gee, J F Robertson, E Gutteridge, I O Ellis, S E Pinder, M Rubini, and R I Nicholson Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer Endocr. Relat. Cancer, July 1, 2005; 12(Supplement_1): S99 - S111. [Abstract] [Full Text] [PDF]

				P. Mendez, I. Azcoitia, and L. M. Garcia-Segura Interdependence of oestrogen and insulin-like growth factor-I in the brain: potential for analysing neuroprotective mechanisms J. Endocrinol., April 1, 2005; 185(1): 11 - 17. [Abstract] [Full Text] [PDF]

				M. Karl, M. Potier, I. H. Schulman, A. Rivera, H. Werner, A. Fornoni, and S. J. Elliot Autocrine Activation of the Local Insulin-Like Growth Factor I System Is Up-Regulated by Estrogen Receptor (ER)-Independent Estrogen Actions and Accounts for Decreased ER Expression in Type 2 Diabetic Mesangial Cells Endocrinology, February 1, 2005; 146(2): 889 - 900. [Abstract] [Full Text] [PDF]

				C. K. Roberts and R. J. Barnard Effects of exercise and diet on chronic disease J Appl Physiol, January 1, 2005; 98(1): 3 - 30. [Abstract] [Full Text] [PDF]

				D. W. Voskuil, A. Vrieling, L. J. van't Veer, E. Kampman, and M. A. Rookus The Insulin-like Growth Factor System in Cancer Prevention: Potential of Dietary Intervention Strategies Cancer Epidemiol. Biomarkers Prev., January 1, 2005; 14(1): 195 - 203. [Abstract] [Full Text] [PDF]

				R. J. Barnard Prevention of Cancer Through Lifestyle Changes Evid. Based Complement. Altern. Med., December 1, 2004; 1(3): 233 - 239. [Abstract] [Full Text] [PDF]

				R. I. Nicholson, I. R. Hutcheson, J. M. Knowlden, H. E. Jones, M. E. Harper, N. Jordan, S. E. Hiscox, D. Barrow, and J. M. W. Gee Nonendocrine Pathways and Endocrine Resistance: Observations with Antiestrogens and Signal Transduction Inhibitors in Combination Clin. Cancer Res., January 1, 2004; 10(1): 346S - 354S. [Abstract] [Full Text] [PDF]